ArticleTranslational vision science & technology2025
Ophthalmic Segmentation and Analysis Software (OASIS): A Comprehensive Tool for Quantitative Evaluation of Meibography Images.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop an interactive image editor, Ophthalmic Segmentation and Analysis Software (OASIS) for automating and improving the analysis of meibography images to gain insight into the progression of meibomian gland dysfunction. Methods: A natural history study was conducted, collecting 2,439 meibography images from 325 patients. Clinicians used OASIS for image analysis, which involved both manual and deep-learning assisted processes. In the manual process, clinicians annotated three distinct masks per image: the eyelid, glands, and gland loss. In the assisted process, OASIS incorporated deep-learning models to infer gland masks, reducing the time required for gland-by-gland annotation. The software's interface provided additional tools for image enhancement and calculation of currently used clinical metrics including the Pult scale. Results: OASIS enabled clinicians to quantitatively analyze MGD in under 3 minutes, representing an 87% reduction in time compared to traditional manual analysis methods. The software accurately calculated Pult meiboscale grades with fair agreement between the clinician and software (kappa = 0.79), demonstrating a high level of consistency. Conclusions: OASIS significantly streamlines the analysis of meibography images and allows for a more objective and efficient evaluation of MGD. By implementing deep learning models for gland inference and providing a suite of custom annotation tools, OASIS may reduce the time burden on clinicians while maintaining accuracy. Translational Relevance: OASIS paves the way for developing quantitative biomarkers for MGD and may have applications in both clinical practices and research. OASIS also further demonstrates the potential for AI-driven tools in improving ophthalmic image analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.